Research Studies
Back to Results
Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Details
Age
Adult
Phase
III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.
Type of Study
Treatment
Locations
Memorial Hospital Central
Memorial Hospital North
Pikes Peak Regional Hospital
Principal Investigator
Uchenna Njiaju
Study ID
Protocol Number: 19-6509
More information available at ClinicalTrials.gov: NCT03975647
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers